The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels

BACKGROUND: Testosterone suppression is the standard treatment for advanced prostate cancer, and it is associated with side-effects that impair patients’ quality of life, like sexual dysfunction, osteoporosis, weight gain, and increased cardiovascular risk. We hypothesized that abiraterone acetate w...

Descripción completa

Detalles Bibliográficos
Autores principales: Werutsky, Gustavo, Maluf, Fernando Cotait, Cronemberger, Eduardo Henrique, Carrera Souza, Vinicius, dos Santos Martins, Suelen Patricia, Peixoto, Fábio, Smaletz, Oren, Schutz, Fábio, Herchenhorn, Daniel, Santos, Telma, Mavignier Carcano, Flavio, Queiroz Muniz, David, Nunes Filho, Paulo R. S., Zaffaroni, Facundo, Barrios, Carlos, Fay, André
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533731/
https://www.ncbi.nlm.nih.gov/pubmed/31122212
http://dx.doi.org/10.1186/s12885-019-5709-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533731/
https://www.ncbi.nlm.nih.gov/pubmed/31122212
http://dx.doi.org/10.1186/s12885-019-5709-y

Ejemplares similares